Clarity Pharmaceuticals, a radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, announced that it has commenced its registrational Phase III diagnostic trial in prostate cancer, with 64Cu-SAR-bisPSMA, CLARIFY. The Urology Cancer Center / XCancer Omaha, NE would be the first clinical site.
The aim of the CLARIFY study is to
assess the diagnostic performance of 64Cu-SAR-bisPSMA to detect
regional nodal metastasis in participants with high-risk prostate cancer prior
to radical prostatectomy. The study expects to recruit 383 participants at
multiple clinical sites across the United States and Australia.
To read more please visit:
Registrational Phase III CLARIFY trial in
prostate cancer commences
Source:
Clarify